Trinity Capital Inc. announced the commitment of $50 million in growth capital to Cala Health, a bioelectronic medicine company developing wearable neuromodulation therapies for tremors.

Cala Health develops and commercializes the Cala kIQ System, an FDA-cleared wearable device designed to help patients manage hand tremors caused by essential tremor and Parkinson's disease. The device is worn on the wrist and measures a patient's unique tremor pattern and delivers individualized nerve stimulation to counteract tremors through noninvasive electrical stimulation. The therapy is prescribed by physicians for use at home, enabling patients to manage their symptoms outside of a clinical setting and regain the ability to perform everyday activities such as reading, writing, and eating and drinking.

"Cala Health has developed a therapy that we believe is simple, personalized, and effective for patients," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are proud to partner with a company that is delivering meaningful improvements in patients' daily lives and look forward to supporting their continued growth and commercial expansion."

"We are pleased to partner with the Trinity team to optimize our capital structure," said Cala CEO Deanna Harshbarger. "This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS therapy to impact the lives of essential tremor and Parkinson's disease patients."